Dr. Daniel Katselnik, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at San Antonio (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 504
Licensed in Texas since 2008, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Texas Medical School at San Antonio
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
TX license N1705 (first issued 2008; active) -
Internal Medicine Physician
TX license N1705 (first issued 2008; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Diabetes and Metabolism Specialists (9 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 504
- Services billed
- 5,034
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,296 | 420 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 293 | 152 |
| Established patient office or other outpatient visit, 10-19 minutes | 147 | 114 |
| Established patient office or other outpatient visit, 20-29 minutes | 129 | 117 |
| Testing of autonomic nervous system function and heart rate response to deep breathing | 126 | 113 |
| Testing of autonomic (sympathetic) nervous system function | 126 | 113 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 109 | 99 |
| Ultrasound scan of head and neck soft tissue | 104 | 102 |
| Measurement of liver stiffness | 85 | 74 |
| New patient office or other outpatient visit, 45-59 minutes | 67 | 67 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ozempic (semaglutide) Other prescribers in Shavano PArk, TX | 259 |
| Levothyroxine Sodium Other prescribers in Shavano PArk, TX | 205 |
| Synthroid (levothyroxine sodium) Other prescribers in Shavano PArk, TX | 172 |
| Rosuvastatin Calcium Other prescribers in Shavano PArk, TX | 142 |
| Metformin Hcl Other prescribers in Shavano PArk, TX | 138 |
| Atorvastatin Calcium Other prescribers in Shavano PArk, TX | 104 |
| Jardiance (empagliflozin) Other prescribers in Shavano PArk, TX | 102 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Shavano PArk, TX | 89 |
| Mounjaro (tirzepatide) Other prescribers in Shavano PArk, TX | 77 |
| Trulicity (dulaglutide) Other prescribers in Shavano PArk, TX | 64 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 37 companies reported 220 payments worth $79,873 in total to this clinician.
| Sanofi-aventis U.S. LLC | $36,471 |
|---|---|
| Dexcom, Inc. | $12,856 |
| Novo Nordisk Inc | $11,795 |
| Siemens Medical Solutions USA, Inc. | $6,455 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $6,368 |
| Lilly USA, LLC | $3,167 |
| Sequel Med Tech, LLC | $863 |
| Amgen Inc. | $222 |
| Compensation for services other than consulting (speaking, faculty) | $50,763 |
|---|---|
| Speaking at a medical education program | $11,107 |
| Travel and Lodging | $7,191 |
| Food and Beverage | $5,596 |
| Consulting Fee | $5,200 |
| Education | $16.27 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi-aventis U.S. LLC Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $7,458 |
| Sanofi-aventis U.S. LLC Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $6,663 |
| Sanofi-aventis U.S. LLC Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $6,396 |
| Dexcom, Inc. May 20, 2025 | Speaking at a medical education program DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology | $5,362 |
| Novo Nordisk Inc Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $3,836 |
| Dexcom, Inc. Feb 5, 2025 | Speaking at a medical education program DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology | $3,447 |
| Siemens Medical Solutions USA, Inc. Jul 15, 2025 | Consulting Fee Atellica IM 1300 Analyzer · DX - Diagnostics incl. all products and services | $3,200 |
| Sanofi-aventis U.S. LLC Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $2,932 |
| Novo Nordisk Inc Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,668 |
| Sanofi-aventis U.S. LLC May 20, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $2,665 |
All 48 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $2,200 |
| Siemens Medical Solutions USA, Inc. Dec 18, 2025 | Consulting Fee Atellica IM 1300 Analyzer · DX - Diagnostics incl. all products and services | $2,000 |
| Sanofi-aventis U.S. LLC Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $2,932 |
| Novo Nordisk Inc Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $494 |
| Lilly USA, LLC Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) | $800 |
| Novo Nordisk Inc Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,093 |
| Novo Nordisk Inc Sep 30, 2025 | Travel and Lodging Ozempic · Diabetes · travel to San Antonio, TX · in-kind | $15.40 |
| Novo Nordisk Inc Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $3,836 |
| Novo Nordisk Inc Sep 25, 2025 | Travel and Lodging Ozempic · Diabetes · travel to The Woodlands, TX · in-kind | $832 |
| Novo Nordisk Inc Sep 25, 2025 | Travel and Lodging Ozempic · Diabetes · travel to The Woodlands, TX · in-kind | $173 |
| Novo Nordisk Inc Sep 25, 2025 | Travel and Lodging Ozempic · Diabetes · travel to The Woodlands, TX · in-kind | $15.00 |
| Dexcom, Inc. Sep 18, 2025 | Speaking at a medical education program DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology | $2,298 |
| Dexcom, Inc. Sep 18, 2025 | Travel and Lodging DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology · travel to Austin, TX | $111 |
| Dexcom, Inc. Sep 18, 2025 | Travel and Lodging DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology · travel to Austin, TX | $52.00 |
| Lilly USA, LLC Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $800 |
| Sanofi-aventis U.S. LLC Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $1,599 |
| Novo Nordisk Inc Aug 18, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $1,163 |
| Sanofi-aventis U.S. LLC Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $1,599 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 5, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $800 |
| Siemens Medical Solutions USA, Inc. Jul 15, 2025 | Consulting Fee Atellica IM 1300 Analyzer · DX - Diagnostics incl. all products and services | $3,200 |
| Siemens Medical Solutions USA, Inc. Jul 15, 2025 | Travel and Lodging Atellica IM 1300 Analyzer · DX - Diagnostics incl. all products and services · travel to Washington, D.C., DC | $780 |
| Siemens Medical Solutions USA, Inc. Jul 15, 2025 | Travel and Lodging Atellica IM 1300 Analyzer · DX - Diagnostics incl. all products and services · travel to Washington, D.C., DC | $215 |
| Dexcom, Inc. Jun 26, 2025 | Travel and Lodging DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology · travel to Orlando, FL | $141 |
| Sanofi-aventis U.S. LLC Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $7,458 |
| Sanofi-aventis U.S. LLC Jun 12, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Plano, TX · in-kind | $705 |
| Sanofi-aventis U.S. LLC Jun 12, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Plano, TX · in-kind | $426 |
| Dexcom, Inc. May 20, 2025 | Speaking at a medical education program DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology | $5,362 |
| Sanofi-aventis U.S. LLC May 20, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $2,665 |
| Sanofi-aventis U.S. LLC May 20, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to San Antonio, TX | $18.99 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 7, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $800 |
| Dexcom, Inc. Apr 25, 2025 | Travel and Lodging DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology · travel to Orlando, FL · in-kind | $611 |
| Novo Nordisk Inc Apr 3, 2025 | Education Ozempic · Diabetes · in-kind | $16.27 |
| Novo Nordisk Inc Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,668 |
| Sanofi-aventis U.S. LLC Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $2,399 |
| Sanofi-aventis U.S. LLC Mar 28, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Las Vegas, NV | $143 |
| Sanofi-aventis U.S. LLC Mar 28, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Las Vegas, NV | $34.99 |
| Sanofi-aventis U.S. LLC Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $6,663 |
| Sanofi-aventis U.S. LLC Mar 27, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Las Vegas, NV · in-kind | $960 |
| Sanofi-aventis U.S. LLC Mar 27, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Las Vegas, NV · in-kind | $203 |
| Dexcom, Inc. Mar 21, 2025 | Travel and Lodging DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology · travel to Orlando, FL · in-kind | $341 |
| Dexcom, Inc. Mar 7, 2025 | Travel and Lodging DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology · travel to Austin, TX · in-kind | $306 |
| Sanofi-aventis U.S. LLC Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $6,396 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $2,200 |
| Sanofi-aventis U.S. LLC Mar 6, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Lyndhurst, NJ · in-kind | $582 |
| Sanofi-aventis U.S. LLC Mar 6, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Lyndhurst, NJ · in-kind | $426 |
| Sanofi-aventis U.S. LLC Mar 6, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Lyndhurst, NJ | $101 |
| Lilly USA, LLC Feb 24, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,200 |
| Dexcom, Inc. Feb 5, 2025 | Speaking at a medical education program DEXCOM G7 GSS (161); DEXCOM STELO GLUCOSE BIOSENSOR · Endocrinology | $3,447 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $195,881 in research payments for these studies, mostly to the institutions running them.
- Remote Use Dexcom G7 Project
Dexcom, Inc. - A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients…
Alnylam Pharmaceuticals Inc. - A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Ascendis Pharma Endocrinology Inc · Completed · NCT05171855
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.